PSA Response to Lenalidomide Therapy in a Pre-Treated Patient with Metastatic Prostate Cancer Refractory to Hormones and Chemotherapy: A Case Report

Hormone-resistant prostate cancer (HRPC) occurs when prostate cancer is no longer responsive to hormone therapy. Treatment options are limited, and there is a clear necessity for therapies that improve outcome. Preclinical and clinical evidence supports the role of the immunomodulatory agent lenalid...

Descripción completa

Detalles Bibliográficos
Autores principales: Gasent Blesa, Joan Manel, Godoy, Miguel Peris, Esparcia, María Fonfría, Mollá, Sara Blasco, Magán, Balbino Mancheño, Sempere Ortells, José Miguel, Sánchez, José Luis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2012
Materias:
Published online: April, 2012
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3364036/
https://www.ncbi.nlm.nih.gov/pubmed/22666210
http://dx.doi.org/10.1159/000336481

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3364036/
https://www.ncbi.nlm.nih.gov/pubmed/22666210
http://dx.doi.org/10.1159/000336481

Ejemplares similares